Press releases
- Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
- Nevro Enters Into Cooperation Agreement With Engaged Capital
- Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
- Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
- Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
- Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting
- Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
- Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.20 |
---|---|
High | 13.20 |
Low | 13.20 |
Bid | 13.30 |
Offer | 13.40 |
Previous close | 12.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 36.40m |
Free float | 34.96m |
P/E (TTM) | -- |
Market cap | 524.86m USD |
EPS (TTM) | -2.57 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:06 BST.
More ▼